Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab after chemotherapy and Endostar in mucosal melanoma
NCT04472806Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in mucosal melanoma (MM), sponsored by Fudan University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04472806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472806.